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Abstract
Platelets are the second most abundant cell type in blood and are essential for maintaining
haemostasis. Their count and volume are tightly controlled within narrow physiological ranges,
but there is only limited understanding of the molecular processes controlling both traits. Here we
carried out a high-powered meta-analysis of genome-wide association studies (GWAS) in up to
66,867 individuals of European ancestry, followed by extensive biological and functional
assessment. We identified 68 genomic loci reliably associated with platelet count and volume
mapping to established and putative novel regulators of megakaryopoiesis and platelet formation.
These genes show megakaryocyte-specific gene expression patterns and extensive network
connectivity. Using gene silencing in Danio rerio and Drosophila melanogaster, we identified 11
of the genes as novel regulators of blood cell formation. Taken together, our findings advance
understanding of novel gene functions controlling fate-determining events during
megakaryopoiesis and platelet formation, providing a new example of successful translation of
GWAS to function.
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To discover novel genetic determinants of megakaryopoiesis and platelet formation, we
performed meta-analyses of GWAS for mean platelet volume (MPV) and platelet count
(PLT). Our analyses included 18,600 (13 studies, MPV) and 48,666 (23 studies, PLT)
individuals of European descent, respectively, and up to ~2.5 million genotyped or imputed
single nucleotide polymorphisms (SNPs)1. Briefly, we tested within each study
(Supplementary Table 1) the associations of MPV and PLT with each SNP using an additive
model; we then combined these study-specific test statistics in a fixed-effects meta-analysis.
To reduce the risk of spurious associations, we applied common stringent quality control
filters and the genomic control method2 to the meta-analysis, which shows no evidence for
residual inflation of summary statistics (Supplementary Fig. 1).
A total of 52 genomic loci reaching statistical significance at the genome-wide adjusted
threshold of P ≤ 5 × 10−8 were discovered in this stage 1 analysis; 55 additional loci reached
suggestive association (5 × 10−8 < P ≤ 5 × 10−6). We tested one SNP per locus in a stage 2
analysis that included in silico and de novo replication data in up to 18,838 individuals from
12 additional studies, confirming 15 additional loci (Supplementary Table 2). One further
independent locus (TRIM58) associated with PLT was identified through detection of
secondary association signals. Overall, 68 independent genomic regions were associated
with PLT and MPV with P ≤ 5 × 10−8, of which 52 are new and 16 were described
previously in Europeans3-6 (Table 1). Of the 68 loci, 43 and 25 loci were associated
significantly with PLT and MPV, respectively; 16 of them reached genome-wide
significance with both traits (Supplementary Fig. 2). This partial overlap reflects the
negative correlation of both traits (gender-adjusted r = −0.49, Fig. 1a) that results from the
tight control of platelet mass (PLT × MPV)7. The association of some loci with both PLT
and MPV may reflect this negative correlation between the two traits or independent
pleiotropic effects of a locus on megakaryopoiesis and platelet formation. The different
statistical power at the two traits and small effect sizes at many loci reduce our power to
discriminate among loci controlling MPV and PLT through analysis of platelet mass. Their
testing will require the collection and analysis of PLT and MPV in large independent
homogeneous cohorts. Some loci, however, have a clear-cut effect. For instance, BAK1
affects PLT specifically, compatible with its role in apoptosis and platelet lifespan.
We further tested the association of the 68 loci in 7,949 (MPV) and 8,295 (PLT) samples of
south Asian and 14,697 (PLT) samples of Japanese8 origin. We detected substantial overlap
of association signals, with effect size and direction highly concordant with findings in
Europeans (Supplementary Fig. 3 and Supplementary Table 3). In the south Asian sample,
15 of the 68 (22.1%) loci were significant after adjustment for multiple testing (P ≤ 7 ×
10−4). In the Japanese sample, 13 of 55 (23.6%) PLT loci showed significance. Moreover,
73 of 84 (87%, South Asians) and 45 of 55 (82%, Japanese) SNPs showed associations with
effect estimates directionally consistent with Europeans. Such concordance is highly
unlikely to be due to chance (P = 2.3 × 10−12 and P = 2.1 × 10−6), and provides independent
validation of the locus discovery in Europeans.
The 68 loci cumulatively explain 4.8% of the phenotypic variance in PLT and 9.9% in
MPV, accounting respectively for average increases of 2.57 × 109 l−1 PLT and 0.10 fl MPV
per copy of allele. These levels of explained variance are in accordance with other GWAS of
complex quantitative traits9. Our results indicate that many other common variants of
similar or lower effect size, rare variants as well as structural variants may also contribute to
the variation of both platelet traits. We used the method of ref. 10 to estimate the number of
additional PLT- and MPV-associated loci having effect sizes comparable to those observed
in our analysis. The method (with caveats discussed in the Supplementary Information)
predicted that 137 and 81 such loci exist for PLT and MPV respectively, accounting for
9.7% and 18.3% of the total phenotypic variance.
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Gene-prioritization strategies
Evidence from recent, highly powered meta-analyses suggests that the association peaks are
enriched for genes controlling key underlying biological pathways11,12. In our case, a large
proportion of the association signals (46 out of 68) had the most significant SNP in stage 1
(‘sentinel SNP’) mapping to within a gene-coding region, including several key regulators of
haemostasis (ITGA2B, F2R, GP1BA), megakaryopoiesis (THPO, MEF2C) and platelet
lifespan (BAK1). Through an unbiased analysis of our GWAS results, we estimated that
PLT-associated SNPs are significantly more likely to map to gene regions than expected by
chance (P < 0.05, Supplementary Fig. 4), suggesting that we may prioritize the search of
additional yet unknown genes controlling these processes in the associated regions. To
define a univocal rule to study the enrichment of functional relationships in associated
genes, we made the choice to focus on a set of 54 ‘core’ genes selected as either containing
the sentinel SNP or mapping to within 10 kb from an intergenic sentinel SNP (Table 2). This
selection strategy is designed to obtain unbiased hypotheses producing interpretable
biological inference for genes near the association signals, but has reduced sensitivity for
genes that map further from the sentinel SNP. For instance VWF, a key regulator of
haemostasis, maps to 55 kb from the sentinel SNP (Supplementary Fig. 3 and
Supplementary Table 4) and is therefore not considered as a core gene. We further note that
this selection strategy does not imply knowledge of the location of causative variants, which
is currently incomplete. A detailed SNP survey showed that at 15 loci the sentinel SNPs
either encoded, or were in high linkage disequilibrium (LD, r2 ≥ 0.8) with, a non-
synonymous variant (Supplementary Table 5); another 11 either matched or were in high
linkage disequilibrium with SNPs associated with expression levels of core genes (or cis-
eQTLs, Supplementary Table 6), indicating that other loci may exert their effect through
regulation of gene expression13. The validation of suggestive causative effects, as well as
the identification of more complex interactions involving other genomic loci (trans eQTLs),
will require a more comprehensive discovery in appropriately powered genomic data sets.
As a first effort to characterize biological connectivity among the core genes, we applied
canonical pathway analyses (see http://www.ingenuity.com), detecting a highly significant
over-representation of core genes in relevant biological functions such as haematological
disease, cancer and cell cycle (Supplementary Table 7). Encouraged by these results, we
extended this effort to construct a comprehensive network of protein-protein interactions
incorporating the core genes. This effort integrated information from public databases
(principally Reactome and IntAct) with careful manual revision of published evidence and
high-throughput gene expression data. The resulting network, which includes 633 nodes and
827 edges, showed extensive connectivity between the proteins encoded by the core genes
with an established functional role in megakaryopoiesis and platelet formation and those
encoded by genes hitherto unknown to be implicated in these processes (Fig. 1b).
Transcriptional patterns of core genes
We next considered whether this connectivity was also reflected in the regulation of core
gene transcription, and whether expression patterns were unique to megakaryocytes. Despite
high levels of correlation in gene expression between different blood cell types (median 5
0.8; median absolute deviation = 0.1)14, we found that core genes tend to have significantly
greater expression in megakaryocytes than in the other blood cells (P = 7.5 × 10−5,
Supplementary Fig. 5a). This observation is compatible with the notion that ultimate steps in
blood cell lineage specification are accompanied, or driven, by the emergence of increasing
numbers of lineage-specific transcripts. To explore this assumption, we used genome-wide
expression arrays to determine changes in global transcript levels during in vitro
differentiation of umbilical-cord blood-derived haematopoietic stem cells to precursors of
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blood cells. We considered five different time points and two cell types, erythroblasts (the
precursors of red blood cells) and megakaryocytes. Notwithstanding high levels of
correlation of gene expression between erythroblasts and megakaryocytes14, core gene
transcripts showed a significant increase over time in megakaryocytes (P = 1.5 × 10−6) but
not in erythroblasts (P = 0.77, Fig. 1c, d; see also Supplementary Fig. 5b). Taken together,
these patterns of core gene expression are consistent with a different regulation of their
transcription in megakaryocytes versus erythroblasts, and with their centrality in
megakaryopoiesis and platelet formation. This hypothesis is also consistent with the
observation that only 5 of the 68 sentinel SNPs exert a significant effect on erythrocyte
parameters (HBS1L-MYB, RCL1, SH2B3, TRIM58 and TMCC2, Supplementary Table 8).
Gene silencing in model organisms
To assess whether core genes are indeed implicated in haematopoiesis, we interrogated the
function of 15 genes using gene silencing in D. rerio and D. melanogaster, and supported
empirical data with published evidence on knockout models in M. musculus (Table 2 and
Supplementary Table 4). In D. rerio, we applied morpholino constructs to silence the
expression of six genes (Fig. 2 and Supplementary Fig. 6) selected to have >50% homology
with the human counterpart and no previous evidence of involvement in haematopoiesis.
Silencing of four genes in D. rerio (arhgef3, ak3, rnf145, jmjd1c) resulted in the ablation of
both primitive erythropoiesis and thrombocyte formation. Silencing of tpma, the orthologue
of TPM1 that is transcribed in megakaryocytes but not in other blood cells, abolished the
formation of thrombocytes but not of erythrocytes. Silencing of ehd3 did not yield a
haematopoietic phenotype. We also screened D. melanogaster RNA interference (RNAi)
knockdown lines for quantitative alterations in the two most prevalent classes of blood
elements: plasmatocytes and crystal cells. The repertoire of blood cells in D. melanogaster,
consisting of about 95% plasmatocytes and 5% crystal cells, is less varied than in
vertebrates. Transcription factors and signalling pathways regulating haematopoiesis have,
however, been conserved throughout evolution15, making the RNAi knockdown studies a
relevant first step towards a better understanding of the putative role of these GWAS genes
in haematopoiesis. Four core-gene D. melanogaster lines (shibire (DNM), ush (ZFPM2),
rpn9 (PSMD13), Brf (BRF1)), as well as five others (sun (ATP5E), CG3704 (XAB1),
Su(var)205 (CBX5), dve (SATB1) and RpL6 (RPL6)), displayed highly reproducible
differences in the numbers of these two cell types (Table 2 and Supplementary Table 4).
Despite widespread differences between mammalian and insect haematopoietic lineages16,
our findings from D. melanogaster provide new and supporting examples of functional
conservation in the control of blood cell formation in invertebrates and vertebrates17-19.
New gene and functional discoveries
The data from studies in D. rerio by us and in M. musculus by others (see Supplementary
Table 4) provided proof-of-concept evidence that our prioritization strategy is appropriate
for selecting novel genes controlling thrombopoiesis and megakaryopoiesis, respectively.
More detailed insights and additional implicated genes will be revealed through the
systematic silencing of all genes in the associated regions. For instance, RNAi knockdown
of dve in D. melanogaster reduces plasmatocyte numbers and increases the number of
crystal cells, thus providing supporting evidence that its non-core genehuman homologue
SATB1 should be prioritized in functional studies. However, the results of the knockdown
study in D. rerio do not clarify at which hierarchical positions in thrombopoiesis and
erythropoiesis the genes exert their effect, requiring further assessment in conditional
knockout models in M. musculus with lineage-specific regulation of gene transcription.
Nevertheless, our results have already allowed novel insights into the genetic control of
these processes. Signalling cascades initiated by thrombopoietin (THPO) and its receptor
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cMPL via the JAK2/STAT3/5A signalling pathway are key regulatory steps initiating
changes in gene expression responsible for driving forward megakaryocyte differentiation20.
Our study highlights several additional signalling proteins implicating potentially important
novel regulatory routes. For instance, two genes encoding guanine nucleotide exchange
factors (DOCK8 and ARHGEF3) were identified. Mendelian mutations of the former are
causative of the hyper-IgE syndrome, but its effect on platelets had not yet been identified.
The silencing of the latter gene in D. rerio resulted in a profound haematopoietic phenotype
characterized by a complete ablation of both primitive erythropoiesis and thrombocyte
formation, demonstrating its novel regulatory role in myeloid differentiation. In a parallel
and in-depth study we demonstrated its novel role in the regulation of iron uptake and
erythroid cell maturation21. A second class of genes also known to critically control early
and late events of megakaryopoiesis are transcription factors. For instance, MYB silencing
by microRNA 150 determines the definitive commitment of the megakaryocyte–erythroblast
precursor to the megakaryocytic lineage15. A further 10 core genes identified in this study
are implicated in the regulation of transcription. Among these, we have demonstrated here
that silencing of rnf145 and jmjd1c in D. rerio severely affects both lineages.
In conclusion, this highly powered study describes a catalogue of known and novel genes
associated with key haematopoietic processes in humans, providing an additional example
of GWAS leading to biological discoveries. We further showed that for a large proportion of
these known and new genes, functional support is achieved from model organisms and by
overlap with genes implicated in inherited Mendelian disorders and in human cancers
because of acquired mutations. In-depth functional studies and comparative analyses will be
necessary to characterize the precise mechanisms by which these new genes and variants
affect haematopoiesis, megakaryopoiesis and platelet formation. Furthermore, we provide
extensive new resources, most notably a freely accessible knowledge base embedded in the
novel protein-protein interaction network, with information about the identified platelet
genes being implicated in Mendelian disorders and results from gene-silencing studies in
model organisms. We anticipate that these resources will help to advance megakaryopoiesis
research, to address key questions in blood stem-cell biology and to propose new targets for
the treatment of haematological disorders. Finally, MPV has been associated with the risk of
myocardial infarction22,23. The contribution of the new loci to the aetiology of acute
myocardial infarction events will require assessment in a prospective setting.
METHODS SUMMARY
A summary of the methods can be found in Supplementary Information and includes
detailed information on: study populations; blood biochemistry measurements; genotyping
methods and quality control filters; genome-wide association and meta-analysis methods;
gene prioritization strategies for functional assessment and network construction; protein-
protein interaction network; in vitro differentiation of blood cells; experimental data sets and
analytical methods for gene expression analysis; zebrafish morpholino knockdown
generation; assessment of other model organism resources.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Protein-protein interaction network and gene transcription patterns
a, Negative correlation between PLT and MPV in a UK sample. The gender-adjusted
correlation coefficient r and trend line are shown. b, Protein–protein interaction network of
platelet loci. For the nodes, genes are represented by round symbols, where node colour
reflects gene transcript level in megakaryocytes on a continuous scale from low (dark green)
to high (white). Grey-coloured round symbols identify first-order interactors identified in
Reactome and IntAct. Core genes not connected to the main network are omitted. The 34
core genes are identified by a blue perimeter. Yellow perimeters identify five additional
genes (VWF, PTPN11, PIK3CG, NFE2 and MYB) with known roles in haemostasis and
megakaryopoiesis and mapping to within the association signals at distances greater than 10
kb from the sentinel SNPs. These genes, which do not conform to the rule for inclusion into
the core gene list, are not considered in further analyses presented in Fig. 2c, d and
Supplementary Fig. 5 and are shown here for illustration purposes only. Network edges were
obtained from the Reactome (blue) and IntAct-like (red) databases and through manual
literature curation (black). The network including the 34 core genes alone contains 633
nodes and 827 edges; after inclusion of the 5 additional genes, the network (shown here)
includes 785 nodes and 1,085 edges. The full network, containing gene expression levels
and other annotation features, is available in Cytoscape25 format for download
(Supplementary Data 1). c, d, Time course experiments of gene expression in
megakaryocytes and erythroblasts. Expression of core genes in log2 transformed signal
intensities (log2 SI) during differentiation of the haematopoietic stem cells into
megakaryocytes (c) or erythroblasts (d), segregated by their trends of statistically significant
increasing (red), decreasing (blue) or unchanged (grey) gene expression. The corresponding
gene list for the three classes is given in Supplementary Data 1.
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Figure 2. Functional assessment of novel loci in D. rerio
Gene-specific morpholinos were injected into wild-type and Tg(cd41:EGFP) embryos at the
one cell stage (Supplementary Fig. 6) to assess alterations in erythropoiesis and
thrombopoiesis. a, Control D. rerio embryo at 72 h post fertilization (h.p.f.); the boxed
region corresponds to images in the middle panels of b–h. b–h, Left: o-dianisidine staining
was used to assess the number of mature erythrocytes at 48 h.p.f.: ehd3 (h) morpholino-
injected embryos showed normal haemoglobin staining, whereas embryos injected with ak3
(c), rnf145 (d), arhgef3 (e) or jmjd1c (g) morpholinos showed a decrease in the number of
haemoglobin-positive cells compared to control embryos (b). Embryos injected with tpma
morpholinos (f) showed normal numbers of erythrocytes but unusual accumulation dorsally
in the blood vessels (compatible with cardiomyopathy). Middle: haematopoietic stem-cell
and thrombocyte development was assessed using the transgenic Tg(cd41:EGFP) line at 72
h.p.f. Embryos injected with the ehd3 (h) morpholino had a normal number of GFP1 cells in
the caudal haematopoietic tissue and circulation, when compared to control embryos (b).
However, GFP1 cells were absent in ak3 (c), rnf145 (d), arhgef3 (e), tpma (f) and jmjd1c (g)
morpholino-injected embryos. Right: One-cell-stage embryos were injected with the
standard control morpholino (b) or gene-specific morpholino (c–h) and monitored during
development. No gross lethality or developmental abnormalities were observed at 72 h.p.f.
in gene-specific morpholino-injected embryos (c–h) compared with the control (b). a and
middle and right panels of b–h, lateral view, anterior left; left panels of b–e, g, h, ventral
view, anterior up; left panel of f, dorsal view, anterior up. The genes appear to be
nonspecifically expressed during embryogenesis as shown by patterns deposited in the ZFIN
resource (http://zfin.org).
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Table 2
Summary of functional evidence for core genes
Sentinel SNP (trait) Core gene (distance in kb)* Phenotype†
rs17396340 (MPV) KIF1B kinesin family member 1B (0) Variant annotation: sentinel SNP in r2 = 1 with eQTL for K1F1B
rs2336384 (PLT) MFN2 mitofusin 2 (0) Variant annotation: sentinel SNP is eQTL for MFN2
rs10914144 (MPV, PLT) DNM3 dynamin 3 (0) shibire (DNM-like): overproliferation of plasmatocytes in Drosophila
(this
study)
rs1172130, rs1668871
(MPV, PLT)
TMCC2 transmembrane and coiled-coil
domain
family 2 (2,481; 0)
Variant annotation: sentinel SNP in r2 = 0.928 with eQTL for RIPK5
rs1260326 (PLT) GCKR glucokinase (hexokinase 4)
regulator (0)
Xab1 (non-core gene): pronounced increase in plasmatocyte and
crystal cell
counts in Drosophila (this study)
rs649729, rs625132
(MPV, PLT)
EHD3 EH-domain-containing 3 (0) ehd3 morpholino-injected embryos had no haematopoietic phenotype
in D.
rerio (this study)
rs17030845 (PLT) THADA thyroid adenoma associated (0) Zfp36l2 (non-core gene): decreased platelet cell number in mouse
rs1354034 (MPV, PLT) ARHGEF3 Rho guanine nucleotide
exchange factor
(GEF) 3 (0)
arhgef3: profound effect on thrombopoiesis and erythropoiesis in D.
rerio
(this study)
rs2227831, rs17568628
(MPV, PLT)
F2R coagulation factor II (thrombin)
receptor
(0; 15,343)
Par1 (F2R): thrombin activation of platelets attenuated in mouse
rs700585, rs4521516
(PLT, MPV)
MEF2C myocyte enhancer factor 2C (0) Mef2: severely impaired megakaryopoiesis with reduced platelet
count and
increased platelet volume in mouse
rs2070729 (PLT) IRF1 interferon regulatory factor 1 (0) Irf1: decreased number of NK lymphocytes in mouse
rs10076782 (MPV) RNF145 ring finger protein 145 (0) rnf145: ablation of thrombopoiesis and erythropoiesis in D. rerio (this
study)
rs210134 (PLT) BAK1 BCL2-antagonist/killer 1 (116) Bak1: genetic ablation of Bcl-xl in mouse leads to thrombocytopenia
by
reducing platelet lifespan and this is corrected by ablation of Bak1
rs6993770 (PLT) ZFPM2 zinc finger protein, multitype 2
(0)
Zfpm2: peripheral haemorrhage in mouse; ush (ZFPM2): reduction in
plasmatocytes and crystal cells in Drosophila (this study)
rs6995402 (PLT) PLEC1 plectin (0) Plec1: impaired leukocyte recruitment to wounds in mouse
rs10813766 (MPV) DOCK8 dedicator of cytokinesis 8 (0) Dock8: decrease in number of B cells and T cells in mouse;
autosomal
recessive hyper-IgE recurrent infection syndrome (OMIM: 243700)
rs409801 (PLT) AK3 adenylate kinase 3 (2,699) ak3: ablation of thrombopoiesis and erythropoiesis in D. rerio (this
study)
rs7075195, rs10761731
(MPV, PLT)
JMJD1C jumonji domain containing 1C
(0)
jmjd1c: ablation of thrombopoiesis and erythropoiesis in D. rerio (this
study)
rs505404, rs17655730
(PLT, MPV)
PSMD13 proteasome (prosome,
macropain) 26S
subunit, non-ATPase, 13 (0); NLRP6
NLR family,
pyrin domain containing 6 (7,856)
rpn9 (PSMD13): reduction in plasmatocyte numbers in Drosophila
(this
study)
rs4246215 (PLT) FEN1 flap structure-specific
endonuclease 1 (0)
Variant annotation: sentinel SNP is eQTL for CPSF7; Fads2 (non-
core gene):
abnormal platelet physiology and decreased platelet aggregation in
mouse
rs4938642 (PLT) CBL Cas-Br-M (murine) ecotropic
retroviral
transforming sequence (0)
Acute myeloid leukaemia (OMIM: 165360); Cbl: increased platelet
numbers, increased thymic CD3 and CD4 expression on T cells in
mouse;
haematopoietic stem/progenitor cells showed enhanced sensitivity to
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cytokines in Cbl-null mice
rs10876550 (MPV) COPZ1 coatomer protein complex,
subunit zeta 1 (6,604)
Variant annotation: sentinel SNP is eQTL for GPR84;
Copz1: iron deficiency in mouse; Nfe2 (non-core): thrombocytopenia
in
mouse; Znf385a (non-core): abnormal platelet morphology in mouse;
Su(var)205 (non-core CBX5): reduction in plasmatocyte number and
overproliferation of crystal cells in Drosophila (this study)
rs3184504 (PLT) SH2B3 SH2B adaptor protein 3 (0) Lnk (SH2B3): increased megakaryopoiesis and platelet count in
mouse;
increased white blood cell counts and decreased platelet count in
mouse;
rpl6 (non-core): reduced plasmatocyte and crystal cell number in
Drosophila
(this study)
rs4148441 (PLT) ABCC4 ATP-binding cassette, sub-family
C
(CFTR/MRP), member 4 (0)
ABCC4 is an active constituent of mediator-storing granules in
human
platelets
rs7317038 (MPV) GRTP1 growth hormone regulated TBC
protein 1 (0)
Variant annotation: sentinel SNP is eQTL for GRTP1; sentinel SNP
in r2 =
0.93 with eQTL for RASA3
rs3000073 (MPV) BRF1 BRF1 homologue, subunit of RNA
polymerase
III transcription initiation factor IIIB (S.
cerevisiae) (0)
brf: reduction in plasmatocyte cell number in Drosophila (this study)
rs3809566 (PLT) TPM1 tropomyosin 1 (alpha) (1,115) Variant annotation: sentinel SNP in r2=1 with eQTL for TPM1; tpma
(TPM1):
total abrogation of thrombopoiesis, but normal erythropoiesis in D.
rerio
(this study)
rs6065 (PLT) GP1BA glycoprotein Ib (platelet), alpha
polypeptide (0)
Bernard–Soulier syndrome (OMIM: 231200), benign Mediterranean
macrothrombocytopenia (OMIM: 153670), pseudo-von Willebrand
disease
(OMIM: 177820); Gp1ba: giant platelets, a low platelet count and
increased
bleeding in mouse; Gp1ba+/− mice show complete inhibition of
arterial
thrombus formation and intermediate platelet numbers
rs708382 (PLT) FAM171A2 family with sequence
similarity 171,
member A2 (1,108); ITGA2B integrin,
alpha 2b (7,207)
Glanzmann thrombasthenia (OMIM: 607759); decreased platelet
count,
abnormal platelet morphology and decreased platelet aggregation in
mouse; itga2b: severely reduced thrombocyte function in D. rerio
rs12969657 (MPV) CD226 CD226 molecule (0) Variant annotation: sentinel SNP is eQTL for CD226; leukocyte
adhesion
deficiency (OMIM: 116920); CD226 mediates adhesion of
megakaryocytic
cells to endothelial cells and inhibition of this diminishes
megakaryocytic
cell maturation; Dnam1 (CD226): cytotoxic T cells and NK cells less
able to
lyse tumours in mouse
rs13042885 (MPV) SIRPA signal-regulatory protein alpha
(4,163)
Sirpa: mild thrombocytopenia in mouse, decreased proportion of
single
positive T cells, enhanced peritoneal macrophage phagocytosis
rs4812048 (MPV) CTSZ cathepsin Z (5,468); TUBB1
tubulin, beta 1 (6,539)
Autosomal dominant macrothrombocytopenia (OMIM: 613112);
Tubb1:
thrombocytopenia resulting from a defect in generating proplatelets in
mouse; prolonged bleeding time and attenuated response of platelets
to
thrombin in mouse; sun (non-core ATP5E): reduction of crystal cell
numbers
in Drosophila (this study)
rs1034566 (PLT) ARVCF armadillo repeat gene deleted in
velocardiofacial
syndrome (0)
Variant annotation: sentinel SNP in r2 = 1 with eQTL for UFD1L
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rs6141 (PLT) THPO thrombopoietin (0) Essential thrombocythemia (OMIM: 187950); Thpo: decrease in
platelet
number and increase in platelet volume in mouse
Information is given only for genes with a haematopoietic phenotype. A more extensive annotation of genes within associated intervals is presented
in Supplementary Table 4. Information on variants associated with gene expression is presented in Supplementary Table 6. No evidence for a
haematopoietic effect was associated with the following core genes: rs3811444 (PLT) (TRIM58 tripartite motif-containing 58 (0)); rs4305276
(MPV) (ANKMY1 ankyrin repeat and MYND domain containing 1 (0)); rs3792366 (PLT) (PDIA5 protein disulphide isomerase family A, member
5 (0)); rs10512627 (MPV) (KALRN kalirin, RhoGEF kinase (0)); rs11734132 (MPV) (KIAA0232 (5,628)); rs441460 (PLT) (LRRC16A leucine-
rich-repeat containing 16A (0)); rs13300663 (PLT) (RCL1 RNA terminal phosphate cyclase-like 1 (0)); rs3731211 (PLT) (CDKN2A cyclin-
dependent kinase inhibitor 2A (0)); rs2950390, rs941207 (MPV, PLT) (PTGES3 prostaglandin E synthase 3 (cytosolic) (1,871); BAZ2A
bromodomain adjacent to zinc finger domain, 2A (0)); rs7961894 (MPV, PLT) (WDR66WD repeat domain 66 (0)); rs8022206 (PLT) (RAD51L1
RAD51-like 1 (S. cerevisiae) (0)); rs8006385 (PLT) (ITPK1 inositol-tetrakisphosphate 1-kinase (0)); rs2297067, rs944002 (PLT, MPV) (C14orf73
exocyst complex component 3-like 4 (0)); rs8076739, rs559972 (MPV, PLT) (TAOK1 TAO kinase 1 (3,357, 0)); rs1697127 (MPV) (AP2B1
adaptor-related protein complex 2, beta 1 subunit (0)); rs11082304 (PLT) (CABLES1 Cdk5 and Abl enzyme substrate 1 (0)); rs8109288 (MPV,
PLT) (TPM4 tropomyosin 4 (0)), rs17356664 (PLT) (EXOC3L2 exocyst complex component 3-like 2 (3,301)); rs2015599 (MPV) (FAR2 fatty
acyl CoA reductase 2 (0)); rs397969 (PLT) (AKAP10 A kinase (PRKA) anchor protein 10 (4,506)); rs11789898 (PLT) (BRD3 bromodomain
containing 3 (0)).
*Core genes are defined as either containing a sentinel SNP or as mapping at less than 10 kb from an intergenic SNP. Distance from nearest gene is
calculated as the absolute distance between SNP and transcription start site of the gene or 3′ end of last exon.
†
Phenotypes are defined from exhaustive search of the OMIM (Online Mendelian Inheritance in Man) database, published in vitro studies for
humans and knockout and knockdown experiments for model organisms for both core and non-core genes. r2 values are calculated from the
HapMap phase 2 CEU panel. Drosophila indicates Drosophila melanogaster.
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